Showing 4301-4310 of 5646 results for "".
- Sight Sciences Receives FDA 510(k) Clearance of the TearCare System for Treatment of Meibomian Gland Dysfunction (MGD)https://modernod.com/news/sight-sciences-receives-fda-510k-clearance-of-the-tearcare-system-for-treatment-of-meibomian-gland-dysfunction-mgd/2480531/Sight Sciences announced FDA 510(k) clearance of the TearCare System for the treatment of meibomian gland dysfunction (MGD), the leading cause of dry eye disease (DED). The indication clears TearCare for the application of localized heat therapy in adult patients with
- Glaukos Announces Retirement of William J. Link, PhD, as Chairman of the Board; and Election of Thomas W. Burns as New Chairmanhttps://modernod.com/news/glaukos-announces-retirement-of-william-j-link-phd-as-chairman-of-the-board-and-election-of-thomas-w-burns-as-new-chairman/2480530/Glaukos announced that William J. Link, PhD, will be retiring as Chairman of the Board, effective December 31, 2021. Dr. Link joined Glaukos’ Board and has served as Chairman since June 2001. In connection with Dr. Link’s retirement, the Board has appointed Thomas W. Burns, Glaukos&rs
- Foundation Fighting Blindness and Nixon Visions Foundation Collaborate to Combat Inherited Retinal Diseaseshttps://modernod.com/news/foundation-fighting-blindness-and-nixon-visions-foundation-collaborate-to-combat-inherited-retinal-diseases/2480523/The Foundation Fighting Blindness announced the launch of the Nixon Visions Foundation Inherited Macular Dystrophy Program formed through a collaboration with the Nixon Visions Foundation. The program will provide funding for six early translational research projects over 3 years for the dev
- Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officerhttps://modernod.com/news/aerie-pharmaceuticals-appoints-raj-kannan-as-chief-executive-officer/2480519/Aerie Pharmaceuticals announced that Raj Kannan will join the company as Chief Executive Officer and a director, effective December 20, 2021. “On behalf of the Board of Directors, I am very pleased to welcome Raj Kannan to Aerie. During the search pro
- NTC and I-MED Pharma Partner to Bring HA-based Dry Eye Ointment to the United States Markethttps://modernod.com/news/ntc-and-i-med-pharma-partner-to-bring-ha-based-dry-eye-ointment-to-the-united-states-market/2480516/NTC Srl and I-MED Pharma announced today that I-Defense, a lubricating ointment containing 0.4% sodium hyaluronate indicated for the relief of dry eyes and lagophthalmos symptoms has been successfully registered with the FDA. It is the first European NTC medical device prod
- Kiora Reports KIO-101 is Safe and Tolerable for Dry Eye Diseasehttps://modernod.com/news/kiora-reports-kio-101-is-safe-and-tolerable-for-dry-eye-disease/2480512/Kiora Pharmaceuticals announced topline data from its vehicle-controlled, randomized safety study of KIO-101 eyedrops. The study evaluated 24 healthy subjects and 21 patients diagnosed with ocular surface inflammation, a driver of dry eye disease. The results demonstrated favorable safe
- I-MED Pharma USA Gains Exclusive Distribution Rights for ESW Vision’s E>Eye and Tearcheck in the United Stateshttps://modernod.com/news/i-med-pharma-usa-gains-exclusive-distribution-rights-for-esw-visions-eeye-and-tearcheck-in-the-united-states/2480505/I-MED Pharma has announced the expansion of their strategic partnership with ESW Vision in France to be their exclusive distributor in the United States. Through I-MED Pharma USA, two dry eye devices will be available directly to all eye care professionals across the country. E>Eye i
- Aerie Signs License Agreement With Santen for Rhopressa and Rocklatan in Europe and Several Other Regionshttps://modernod.com/news/aerie-concludes-exclusive-license-agreement-with-santen-for-rhopressa-and-rocklatan-in-europe-and-several-other-regions/2480495/Aerie Pharmaceuticals announced that Aerie and Santen have entered into an exclusive development and commercialization agreement for Rhopressa/Rhokiinsa (netarsudil ophthalmic solution) 0.02% and Rocklatan/Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. The expan
- New Technology, Greater Patient Awareness Will Help Drive Gains in Premium Cataract Surgeryhttps://modernod.com/news/new-technology-greater-patient-awareness-will-help-drive-gains-in-premium-cataract-surgery/2480489/Gains in the premium cataract surgery market over the next 5 years will be driven by technological improvements, growing value awareness among patients, declining reimbursement in the public
- Alimera Sciences Welcomes Ophthalmic Strategic Consultant Erin Parsons to Its Board of Directorshttps://modernod.com/news/alimera-sciences-welcomes-ophthalmic-strategic-consultant-erin-parsons-to-its-board-of-directors/2480483/Alimera Sciences announced the addition of Erin Parsons to its Board of Directors. Ms. Parsons has more than 20 years of experience working in the ophthalmic industry overseeing scientific strategy, medical communications, advocacy development, and peer-to-peer educational programs, muc